- Home
- STTK vs VIGL Comparison
STTK vs VIGL Comparison
Compare STTK & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- VIGL
- Stock Information
- Founded
- STTK 2016
- VIGL 2020
- Country
- STTK United States
- VIGL United States
- Employees
- STTK N/A
- VIGL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- VIGL Health Care
- Exchange
- STTK Nasdaq
- VIGL Nasdaq
- Market Cap
- STTK 37.6M
- VIGL 134.9M
- IPO Year
- STTK 2020
- VIGL 2022
- Fundamental
- Price
- STTK $0.82
- VIGL $8.07
- Analyst Decision
- STTK Hold
- VIGL Buy
- Analyst Count
- STTK 4
- VIGL 7
- Target Price
- STTK $3.00
- VIGL $8.00
- AVG Volume (30 Days)
- STTK 480.9K
- VIGL 1.1M
- Earning Date
- STTK 07-31-2025
- VIGL 08-12-2025
- Dividend Yield
- STTK N/A
- VIGL N/A
- EPS Growth
- STTK N/A
- VIGL N/A
- EPS
- STTK N/A
- VIGL N/A
- Revenue
- STTK $4,606,000.00
- VIGL N/A
- Revenue This Year
- STTK N/A
- VIGL N/A
- Revenue Next Year
- STTK N/A
- VIGL N/A
- P/E Ratio
- STTK N/A
- VIGL N/A
- Revenue Growth
- STTK 69.65
- VIGL N/A
- 52 Week Low
- STTK $0.69
- VIGL $1.31
- 52 Week High
- STTK $4.99
- VIGL $8.06
- Technical
- Relative Strength Index (RSI)
- STTK 38.86
- VIGL 87.53
- Support Level
- STTK $0.75
- VIGL $7.86
- Resistance Level
- STTK $0.85
- VIGL $8.06
- Average True Range (ATR)
- STTK 0.09
- VIGL 0.02
- MACD
- STTK -0.01
- VIGL -0.13
- Stochastic Oscillator
- STTK 9.59
- VIGL 84.62
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.